Program
Folfox protocol
Also written as “sunitinib + FOLFOX”, “FOLFOX” and “FOLFOX regimen”.
Its studies are mostly in Colorectal Neoplasms · Cholangiocarcinoma · Stomach Neoplasms · Neoplasms, led by 11 companies.
Drug pageFolfox protocol: every studyMany companies study it; this page follows only the 15 they lead. All 89 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 31 open or running | phase 1since Feb 23, 2009 | Feb 23, 2009 | Aug 31, 2030phase 1 · NCT04929223 |
| AstraZenecaits history only | 21 open or running | phase 3since Nov 13, 2006 | Nov 13, 2006 | Nov 30, 2027phase 2 · NCT05702229 |
| Pfizerits history only | 20 open or running | phase 2since Feb 1, 2008 | Jan 11, 2008 | none ahead |
| Alethia Biotherapeuticsits history only | 11 open or running | phase 2since Nov 17, 2023 | Nov 17, 2023 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Mar 20, 2009 | Mar 20, 2009 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since May 24, 2007 | May 24, 2007 | none ahead |
| Cardiff Oncologyits history only | 11 open or running | phase 2since Oct 24, 2023 | Oct 24, 2023 | Apr 16, 2027phase 2 · NCT06106308 |
| Fosun Pharmaits history only | 11 open or running | phase 2since Apr 2, 2025 | Apr 2, 2025 | Apr 30, 2028phase 2 · NCT06936527 |
| Genmabits history only | 11 open or running | phase 2since Apr 4, 2018 | Apr 4, 2018 | May 2028phase 2 · NCT03526835 |
| Lisata Therapeuticsits history only | 10 open or running | phase 2since Jan 26, 2023 | Jan 26, 2023 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 2since Oct 22, 2008 | Oct 22, 2008 | none ahead |
Also a collaborator on its studies: Merck Pte. Ltd., Singapore.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 13, 2006.
- May 24, 2007Bristol-Myers Squibb’s first study: phase 1 study in NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00479583 · 25 enrolled · United States, France
- Jan 11, 2008Pfizer’s first study: phase 1 study in Colorectal NeoplasmsNew to PfizerPfizer · NCT00599924 · 53 enrolled · United States
- Feb 1, 2008Phase 2 study in Colorectal NeoplasmsPfizer · NCT00615056 · 171 enrolled · United States, Canada, France and more
- Oct 22, 2008Merck KGaA, Darmstadt, Germany’s first study: phase 2 study in Colorectal NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00778830 · 289 enrolled · Singapore
- Feb 23, 2009Hoffmann-La Roche’s first study: phase 1 study in Colorectal NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT00851136 · 9 enrolled
- Mar 5, 2009Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT00873756 · 23 enrolled · United States
- Mar 20, 2009Amgen’s first study: phase 2 study in Colorectal NeoplasmsNew to AmgenAmgen · NCT00866944 · 35 enrolled · France, Germany
- Apr 4, 2018Genmab’s first study: phase 2 study in Colorectal NeoplasmsNew to GenmabGenmab · NCT03526835 · 560 planned · United States, Belgium, France and more
- Jun 11, 2021Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT04929223 · 542 planned · United States, Australia, Canada and more
- Dec 7, 2022Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
- Jan 26, 2023Lisata Therapeutics’ first study: phase 2 study in CholangiocarcinomaNew to Lisata TherapeuticsLisata Therapeutics · NCT05712356 · 66 enrolled · United States
- Oct 24, 2023Cardiff Oncology’s first study: phase 2 study in Colorectal NeoplasmsNew to Cardiff OncologyCardiff Oncology · NCT06106308 · 110 enrolled · United States
- Nov 17, 2023Alethia Biotherapeutics’ first study: phase 2 study in Colorectal NeoplasmsNew to Alethia BiotherapeuticsAlethia Biotherapeutics · NCT06225843 · 17 planned · Canada
- Apr 2, 2025Fosun Pharma’s first study: phase 2 study in Colorectal NeoplasmsNew to Fosun PharmaFosun Pharma · NCT06936527 · 102 planned · China
Ahead
- Apr 16, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCardiff Oncology · NCT06106308
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229
- Apr 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsFosun Pharma · NCT06936527
- May 2028Primary completion: phase 2 study in Colorectal NeoplasmsGenmab · NCT03526835
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06936527Colorectal Neoplasms · China | 2 | By invitation | Fosun Pharma | Apr 30, 2028 | 102 |
| NCT06225843Colorectal Neoplasms · Canada | 2 | Recruiting | Alethia Biotherapeutics | Mar 2026 | 17 |
| NCT06106308Colorectal Neoplasms · United States | 2 | Active, not recruiting | Cardiff Oncology | Apr 16, 2027 | 110 |
| NCT05712356Cholangiocarcinoma · United States | 2 | Completed | Lisata Therapeutics | Apr 5, 2026 | 66 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | AstraZeneca | Nov 30, 2027 | 163 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 542 |
| NCT03526835Colorectal Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Genmab | May 2028 | 560 |
| NCT00866944Colorectal Neoplasms · France, Germany | 2 | Completed | Amgen | Jul 2011 | 35 |
| NCT00873756Colorectal Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Mar 2014 | 23 |
| NCT00851136Colorectal Neoplasms | 1 | Completed | Hoffmann-La Roche | Jun 2010 | 9 |
| NCT00778830Colorectal Neoplasms · Singapore | 2 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2014 | 289 |
| NCT00615056Colorectal Neoplasms · United States, Canada, France and more | 2 | Completed | Pfizer | Mar 2011 | 171 |
| NCT00599924Colorectal Neoplasms · United States | 1 | Completed | Pfizer | Nov 2008 | 53 |
| NCT00479583Neoplasms · United States, France | 1 | Completed | Bristol-Myers Squibb | Apr 2010 | 25 |
| NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more | 3 | Completed | AstraZeneca | Mar 2010 | 1,254 |
How it is read
Names in the registry
- “sunitinib + FOLFOX”, 7 entries
- “FOLFOX”, 6 entries
- “FOLFOX regimen”, 2 entries
- “FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])”, 2 entries
- “MCLA-158 + FOLFOX”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 12 studies
- Cholangiocarcinoma, 1 study
- Stomach Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.